CINCINNATI--(BUSINESS WIRE)--Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the EPIK™ miRNA Panel Assays, developed for miRNA profiling of cancer samples, biofluids, and stem cells. The EPIK miRNA Panel Assays are the result of a collaboration between MiRXES in Singapore and Bioline.
Using a novel approach developed by MiRXES, combinations of miRNA specific reverse transcriptase and hemi-nested real-time PCR primers have been designed to maximize miRNA detection sensitivity and specificity. The real-time PCR assays use SensiSMART™ with SYBR® Green to enable detection of extremely low levels of miRNA with high specificity, allowing the discrimination between closely related miRNA sequences. This highly reproducible, sensitive platform has been validated independently by molecular diagnostic and pharmaceutical laboratories and showed superior performance to existing commercial assays. The EPIK miRNA Panel Assays provide researchers with a convenient way to quickly analyze miRNAs that suggest a correlation with the dysregulations in various cancers, in maintenance, differentiation and reprogramming of stem cells and to look at circulating miRNAs that are regarded as a promising new class of biomarkers.
Marco Calzavara, President of Bioline commented, “The release of the EPIK miRNA Panel Assays follows the release of the ISOLATE II miRNA, Plant miRNA, Biofluids RNA, RNA/DNA/Protein and FFPE RNA/DNA Kits earlier this year and shows the continued commitment of Bioline to produce high quality miRNA kits to help researchers with miRNA expression profiling and quantification and in biomarker discovery.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are excited about the release of the EPIK miRNA Panel Assays and the enhanced performance they provide for our important life science customers in the research, molecular diagnostic and pharmaceutical laboratories and biotechnology companies. We remain committed to the continued expansion of the rapidly growing portfolio of highly specialized molecular biology products from Bioline.”
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard L. Eberly, email@example.com
MiRXES is a spin-off from the Bioprocessing Technology Institute of the Agency of Science Technology and Research (A*STAR) and is supported by Exploit Technologies. MiRXES collaborates extensively with academic, clinical and industrial partners locally and globally in advancing the science and business of miRNA. MiRXES is a key partner to Singapore’s National Diagnostic Initiative (Diagnostic Development Hub). MiRXES’ website is www.mirxes.com.